INOVIO PHARMACEUTICALS, INC.
No SEC Form 4 filings for $INO in the last 30 days.
See all $INO insider activity →Inovio Pharmaceuticals (INO) awaits a U.S. FDA decision on its Biologics License Application for INO-3107, a potential treatment for recurrent respiratory papillomatosis, by October 30, 2026. The disease is caused by HPV-6 and HPV-11 and involves wart-like tumors in the respiratory tract.
INOVIO won an $80.4M court judgment against defendants for breaching a supply agreement, but their financial condition may hinder collection. INOVIO plans to pursue recovery. INOVIO is a biotech company focused on DNA medicines for cancer and infectious diseases. The company cautioned that collection is uncertain and may be reduced or reversed.
The FDA is expected to make key decisions in October on drugs from GSK, Inovio Pharmaceuticals, Agios, and Sun Pharma. GSK's Bepirovirsen for hepatitis B has a decision date of October 26, supported by Phase 3 trials showing a 19% functional cure rate. Inovio's INO-3107 for respiratory papillomatosis is up for review on October 30, with 81.3% of patients requiring fewer surgeries post-treatment.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning INO (INOVIO PHARMACEUTICALS, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INO coverage spans regulation, earnings and corporate actions.
The pending FDA decision creates binary risk for INO; approval could trigger a sharp rally, while a denial may cause a sell‑off.
Potential shortfall in judgment recovery could pressure INOVIO's share price.
Approval would be a first for the therapy and could lift INO stock; rejection would hurt.
Regulatory decision could shift company from clinical to commercial stage.
Regulatory inspection completion plus a defined label-negotiation window reduces near-term uncertainty on the accelerated-approval path for INO-3107, while confirmatory-trial protocol feedback remains a key overhang.
AlphAI scores every news story that mentions INO with an AI model for sentiment and relevance, and aggregates insider trades from INOVIO PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Inovio Pharmaceuticals (INO) awaits a U.S. FDA decision on its Biologics License Application for INO-3107, a potential treatment for recurrent respiratory papillomatosis, by October 30, 2026. The disease is caused by HPV-6 and HPV-11 and involves wart-like tumors in the respiratory tract.
1 min readINOVIO won an $80.4M court judgment against defendants for breaching a supply agreement, but their financial condition may hinder collection. INOVIO plans to pursue recovery. INOVIO is a biotech company focused on DNA medicines for cancer and infectious diseases. The company cautioned that collection is uncertain and may be reduced or reversed.
1 min readThe FDA is expected to make key decisions in October on drugs from GSK, Inovio Pharmaceuticals, Agios, and Sun Pharma. GSK's Bepirovirsen for hepatitis B has a decision date of October 26, supported by Phase 3 trials showing a 19% functional cure rate. Inovio's INO-3107 for respiratory papillomatosis is up for review on October 30, with 81.3% of patients requiring fewer surgeries post-treatment.
2 min readArcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.
2 min readInovio Pharmaceuticals said the FDA completed all scheduled pre-licensure inspections, with one observation addressed. Management reiterated that INO-3107 meets accelerated approval criteria and expects label negotiations in Sept 2026 ahead of an Oct 30 PDUFA. Cash runway extends into late Q1 2027 after a July 2026 $18.3M equity offering; Q3 2026 net cash burn is $18M.
6 min readINOVIO (NASDAQ: INO) reported Q2 2026 results and said the FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is progressing toward a PDUFA target date of Oct. 30, 2026. Cash and investments were $36.7M at June 30, 2026. Net loss was $6.0M. ApolloBio reported positive Phase 3 topline results for VGX-3100 in China.
6 min readINOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights • U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a tar
5 min readInovio (NASDAQ: INO) said it will release its second-quarter 2026 financial results after the market close on Aug. 12, 2026. After the release, the company will hold a live conference call and webcast at 4:30 p.m. ET with analyst Q&A and a 90-day replay.
1 min readINOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA – July 29, 2026 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related
4 min readInovio Pharmaceuticals (NASDAQ:INO) shares fell 30.8% in Thursday premarket after the company priced a $20 million underwritten public offering at $0.95 per share. It will sell 21,052,632 shares plus warrants for up to 42,105,264 shares, with warrants priced at a $1.10 exercise price. Piper Sandler is sole manager.
2 min read
